The share price of dual-listed cancer diagnostics company Pacific Edge has plummeted in early trading after it said proposed changes to the way its CX-bladder tests were reimbursed have the potential to be disruptive. It stopped short of quantifying it.
If the proposed changes were approved
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
